Social Media in the Pharmaceutical Industry

This white paper, presented by Astrazeneca, is a report of the feedback from active participants in social media, providing insights into the beliefs of various stakeholders about how pharmaceutical manufacturers have engaged in social media.

The paper also contains a constructive review of AstraZeneca's social media principles and proposed regulatory framework.

It summarises and addresses key discussion points that arose from both the Social Media Roundtable and DPE, as well as several considerations for the FDA in its development of social media guidance.

In the paper, Astrazeneca put forth five principles required for appropriate pharmaceutical manufacturer engagement in social media.

The white paper says the FDA should engage with the pharmaceutical industry to help them research and resolve issues raised by social media.